Cabaletta Bio, Inc. (CABA)
$3.18-$0.20 (-5.92%) Today
Latest CABA Insider Trades
David J. Chang - OfficerOpen-market purchase
David J. Chang - Officer
Catherine Bollard
Mark SimonCabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 5 | 110,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
22 Form 4 filings on record, the earliest from May 19, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Shawn Tomasello | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Mark Simon | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Catherine Bollard | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Scott C. Brun | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Arun Das - Officer | Grant or award | Stock Option (Right to Buy) | 175,000 | $0.00 | - | |
| Michael Gerard - Officer | Grant or award | Stock Option (Right to Buy) | 175,000 | $0.00 | - | |
| Gwendolyn Binder - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| David J. Chang - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| Steven Nichtberger - Officer | Grant or award | Stock Option (Right to Buy) | 674,000 | $0.00 | - | |
| Anup Marda - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| David J. Chang - Officer | Open-market purchase | Common Stock | 8,800 | $2.26 | $20K | |
| Gwendolyn Binder - Officer | Open-market purchase | Common Stock | 11,312 | $2.19 | $25K | |
| Shawn Tomasello | Open-market purchase | Common Stock | 22,725 | $2.21 | $50K | |
| Steve Gavel - Officer | Open-market purchase | Common Stock | 22,170 | $2.27 | $50K | |
| Catherine Bollard | Open-market purchase | Common Stock | 4,405 | $2.27 | $10K | |
| Steven Nichtberger - Officer | Open-market purchase | Common Stock | 45,000 | $2.24 | $101K | |
| Mark Simon | Open-market purchase | Common Stock | 11,061 | $2.28 | $25K | |
| Michael Gerard - Officer | Open-market purchase | Common Stock | 6,600 | $2.27 | $15K | |
| Steve Gavel - Officer | Grant or award | Stock Option (Right to Buy) | 275,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Derivative | Stock Option (Right to Buy) | 46,428 | $0.00 | - | |
| Richard C. Henriques Jr. | Grant or award | Stock Option (Right to Buy) | 46,428 | $0.00 | - | |
| Richard C. Henriques Jr. | Derivative | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Derivative | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Derivative | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Richard C. Henriques Jr. | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - |
Cabaletta Bio, Inc. (CABA) had 5 insider filings in the last 90 days, with the most recent on 2026-06-10. The full record for CABA runs to 22 Form 4 filings, the earliest from 2025-05-19. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CABA were filed in the last 90 days. 8 purchases are on record for this company.
No insider sales of CABA were filed in the last 90 days.
This page tracks CABA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CABA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
